Columbus Circle Investors Buys New Position in Syndax Pharmaceuticals, Inc. (SNDX)
Columbus Circle Investors acquired a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 42,514 shares of the company’s stock, valued at approximately $497,000. Columbus Circle Investors owned 0.17% of Syndax Pharmaceuticals at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. New York State Common Retirement Fund boosted its position in shares of Syndax Pharmaceuticals by 421.9% during the second quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after buying an additional 7,599 shares during the period. Airain ltd acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $150,000. Bank of Montreal Can acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $158,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Syndax Pharmaceuticals during the third quarter worth approximately $163,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $192,000. Institutional investors and hedge funds own 63.22% of the company’s stock.
Several equities analysts have recently issued reports on the company. Oppenheimer Holdings, Inc. boosted their price objective on Syndax Pharmaceuticals to $29.00 and gave the stock an “outperform” rating in a research report on Friday, August 11th. Citigroup Inc. set a $20.00 price objective on Syndax Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Nomura reduced their price objective on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 11th. Instinet reiterated a “buy” rating and set a $22.00 price objective (down from $27.00) on shares of Syndax Pharmaceuticals in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Two investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.13.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/columbus-circle-investors-buys-new-position-in-syndax-pharmaceuticals-inc-sndx/1721647.html.
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) opened at $8.25 on Thursday. Syndax Pharmaceuticals, Inc. has a twelve month low of $6.31 and a twelve month high of $15.70.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, November 7th. The company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. Syndax Pharmaceuticals had a negative return on equity of 57.90% and a negative net margin of 4,304.34%. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the previous year, the company earned ($0.84) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.03 EPS for the current year.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.